Zhigang Peng

机构：Huangshan University, The Central Hospital of Xiao gan, Xiaogan First People's Hospital, China Nonferrous Metals Changsha Investigation Design Institute, Hubei Engineering University · ORCID：0000-0001-7408-9237

发表论文 133 篇 · 总被引 1949 次 · h-index 23

代表论文

• Regulation of cellular senescence in tumor progression and therapeutic targeting: mechanisms and pathways (2025 · Molecular Cancer · 被引 70)
• An in-depth review: Unraveling the extraction, structure, bio-functionalities, target molecules, and applications of pectic polysaccharides (2024 · Carbohydrate Polymers · 被引 56)
• Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial (2025 · Signal Transduction and Targeted Therapy · 被引 20)
• Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T‐cell and natural killer‐cell neoplasms: A phase 2, multicenter, open‐label, single‐arm trial (2025 · Cancer · 被引 11)
• Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial (2025 · Nature Communications · 被引 6)
• A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma (2025 · Journal of Hematology & Oncology · 被引 5)